recent publications
-
academic article
- Firstenberg, M. S., Dyke, C. M., Angiolillo, D. J., Ramaiahm, C., Price, M., Brtko, M., Welsby, I., Chandna, H., Holmes, D. R., Voeltz, M., Tummala, P., Hutyra, M., et al. Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery Heart Surgery Forum 2013 16:E60-E69 DOI:10.1532/hsf98.20121103 PMID:23625478
- Bhatt, D. L., Pare, G., Eikelboom, J. W., Simonsen, K. L., Emison, E. S., Fox, K. A. A., Steg, P. G., Montalescot, G., Bhakta, N., Hacke, W., Flather, M. D., Mak, K. H., et al. The relationship between cyp2c19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: The charisma genetics study European Heart Journal 2012 33:2143-2150 DOI:10.1093/eurheartj/ehs059 PMID:22450429
- Angiolillo, D. J., Firstenberg, M. S., Price, M. J., Tummala, P. E., Hutyra, M., Welsby, I. J., Voeltz, M. D., Chandna, H., Ramaiah, C., Brtko, M., Cannon, L., Dyke, C., et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery a randomized controlled trial JAMA-Journal of the American Medical Association 2012 307:265-274 DOI:10.1001/jama.2011.2002 PMID:22253393 PMCID:PMC3774162
- Berger, J. S., Bhatt, D. L., Steg, P. G., Steinhubl, S. R., Montalescot, G., Shao, M. Y., Hacke, W., Fox, K. A., Berger, P. B., Topol, E. J., Lincoff, A. M., Investigators, Charisma Bleeding, mortality, and antiplatelet therapy: Results from the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (charisma) trial American Heart Journal 2011 162:98-105 DOI:10.1016/j.ahj.2011.04.015 PMID:21742095
- Weber, M., Bhatt, D. L., Brennan, D. M., Hankey, G. J., Steinhubl, S. R., Johnston, S. C., Montalescot, G., Mak, K. H., Fox, K. A. A., Easton, D. J., Topol, E. J., Hamm, C. W., et al. High-sensitivity c-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: A substudy from the charisma trial Heart 2011 97:626-631 DOI:10.1136/hrt.2010.210419 PMID:21393433
- Topol, E. J., Bousser, M. G., Fox, K. A. A., Creager, M. A., Despres, J. P., Easton, J. D., Hamm, C. W., Montalescot, G., Steg, P. G., Pearson, T. A., Cohen, E., Gaudin, C., et al. Rimonabant for prevention of cardiovascular events (crescendo): A randomised, multicentre, placebo-controlled trial Lancet 2010 376:517-523 DOI:10.1016/s0140-6736(10)60935-x PMID:20709233
- Berger, P. B., Bhatt, D. L., Fuster, V., Steg, P. G., Fox, K. A. A., Shao, M. Y., Brennan, D. M., Hacke, W., Montalescot, G., Steinhubl, S. R., Topol, E. J., Investigators, Charisma Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease Circulation 2010 121:2575-2583 DOI:10.1161/circulationaha.109.895342 PMID:20516378
- Montalescot, G., Ellis, S. G., de Belder, M. A., Janssens, L., Katz, O., Pluta, W., Ecollan, P., Tendera, M., van Boven, A. J., Widimsky, P., Andersen, H. R., Betriu, A., et al. Enoxaparin in primary and facilitated percutaneous coronary intervention a formal prospective nonrandomized substudy of the finesse trial (facilitated intervention with enhanced reperfusion speed to stop events) JACC-Cardiovascular Interventions 2010 3:203-212 DOI:10.1016/j.jcin.2009.11.012 PMID:20170878
- Berger, J. S., Bhatt, D. L., Steinhubl, S. R., Shao, M. Y., Steg, P. G., Montalescot, G., Hacke, W., Fox, K. A., Lincoff, A. M., Topol, E. J., Berger, P. B., Investigators, Charisma Smoking, clopidogrel, and mortality in patients with established cardiovascular disease Circulation 2009 120:2337-2344 DOI:10.1161/circulationaha.109.866533 PMID:19933933 PMCID:PMC2814172
- Ellis, S. G., Tendera, M., de Belder, M. A., van Boven, A. J., Widimsky, P., Andersen, H. R., Betriu, A., Savonitto, S., Adamus, J., Peruga, J. Z., Hamankiewicz, M., Pluta, W., et al. 1-year survival in a randomized trial of facilitated reperfusion results from the finesse (facilitated intervention with enhanced reperfusion speed to stop events) trial JACC-Cardiovascular Interventions 2009 2:909-916 DOI:10.1016/j.jcin.2009.07.009 PMID:19850248
- Herrmann, H. C., Lu, J. D., Brodie, B. R., Armstrong, P. W., Montalescot, G., Betriu, A., Neuman, F. J., Effron, M. B., Barnathan, E. S., Topol, E. J., Ellis, S. G., Investigators, Finesse Benefit of facilitated percutaneous coronary intervention in high-risk st-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals JACC-Cardiovascular Interventions 2009 2:917-924 DOI:10.1016/j.jcin.2009.06.018 PMID:19850249
- Collet, J. P., Montalescot, G., Steg, P. G., Steinhubl, S. R., Fox, K. A. A., Hu, T. F., Johnston, S. C., Hamm, C. W., Bhatt, D. L., Topol, E. J. Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the charisma trial Archives of Cardiovascular Diseases 2009 102:485-496 DOI:10.1016/j.acvd.2009.03.012 PMID:19664568
- Dasgupta, A., Steinhubl, S. R., Bhatt, D. L., Berger, P. B., Shao, M. Y., Mak, K. H., Fox, K. A. A., Montalescot, G., Weber, M. A., Haffner, S. M., Dimas, A. P., Steg, P. G., et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial) American Journal of Cardiology 2009 103:1359-1363 DOI:10.1016/j.amjcard.2009.01.342 PMID:19427428
- Mak, K. H., Bhatt, D. L., Shao, M., Haffner, S. M., Hamm, C. W., Hankey, G. J., Johnston, S. C., Montalescot, G., Steg, P. G., Steinhubl, S. R., Fox, K. A. A., Topol, E. J. The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease European Heart Journal 2009 30:857-865 DOI:10.1093/eurheartj/ehp037 PMID:19233855
- Steinhubl, S. R., Bhatt, D. L., Brennan, D. M., Montalescot, G., Hankey, G. J., Eikelboom, J. W., Berger, P. B., Topol, E. J., Investigators, Charisma Aspirin to prevent cardiovascular disease: The association of aspirin dose and clopidogrel with thrombosis and bleeding Annals of Internal Medicine 2009 150:379-386 DOI:10.7326/0003-4819-150-6-200903170-00006 PMID:19293071
- Eikelboom, J. W., Hankey, G. J., Thom, J., Bhatt, D. L., Steg, P. G., Montalescot, G., Johnston, S. C., Steinhubl, S. R., Mak, K. H., Easton, J. D., Hamm, C., Hu, T. F., et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid determinants and effect on cardiovascular risk Circulation 2008 118:1705-1712 DOI:10.1161/circulationaha.108.768283 PMID:18838564
- Ellis, S. G., Tendera, M., de Belder, M. A., van Boven, A. J., Widimsky, P., Janssens, L., Andersen, H. R., Betriu, A., Savonitto, S., Adamus, J., Peruga, J. Z., Kosmider, M., et al. Facilitated pci in patients with st-elevation myocardial infarction New England Journal of Medicine 2008 358:2205-2217 DOI:10.1056/NEJMoa0706816 PMID:18499565
- Wang, T. H., Bhatt, D. L., Fox, K. A. A., Steinhubl, S. R., Brennan, D. M., Hacke, W., Mak, K. H., Pearson, T. A., Boden, W. E., Steg, P. G., Flather, M. D., Montalescot, G., et al. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the charisma trial European Heart Journal 2007 28:2200-2207 DOI:10.1093/eurheartj/ehm274 PMID:17673448
- Bhatt, D. L., Flather, M. D., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., Hamm, C. W., Hankey, G. J., et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the charisma trial Journal of the American College of Cardiology 2007 49:1982-1988 DOI:10.1016/j.jacc.2007.03.025 PMID:17498584
- Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., Flather, M. D., Haffner, S. M., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events New England Journal of Medicine 2006 354:1706-1717 DOI:10.1056/NEJMoa060989 PMID:16531616
- Bhatt, D. L., Fox, K. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., Flather, M. D., Haffner, S. M., et al. A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial American Heart Journal 2005 150:401.e1-401.e7 DOI:10.1016/j.ahj.2005.03.017 PMID:16169314
- Ellis, S. G., Armstrong, P., Betriu, A., Brodie, B., Herrmann, H., Montalescot, G., Neumann, F. J., Smith, J. J., Topol, E., Investigators, Finesse Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: Design and rationale of the facilitated intervention with enhanced reperfusion speed to stop events (finesse) trial American Heart Journal 2004 147 DOI:10.1016/j.ahj.2003.07.025
- Anderson, K. M., Califf, R. M., Stone, G. W., Neumann, F. J., Montalescot, G., Miller, D. P., Ferguson, J. J., Willerson, J. T., Weisman, H. F., Topol, E. J. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention Journal of the American College of Cardiology 2001 37:2059-2065 DOI:10.1016/s0735-1097(01)01290-6 PMID:11419888